CytoSorbents Shines with Impressive Q4 Results
Strong Product Revenue Growth and Gross Margin Rebound
CytoSorbents has reported a remarkable Q4, with product revenue growth estimated to be between 22% and 25% year-over-year, according to D. Boral Capital. This impressive growth is a testament to the company’s operational resilience and efficiency improvements.
Gross Margin Rebound a Key Highlight
The company’s gross margin has also seen a significant rebound, reaching around 70%. This is a clear indication of CytoSorbents’ ability to execute effectively and capitalize on the growing demand for its flagship product, CytoSorb.
Buy Rating and $10 Price Target Reiterated
D. Boral Capital has reiterated its Buy rating on CytoSorbents’ shares, with a price target of $10. This is a vote of confidence in the company’s strong execution and its ability to drive growth.
Growing Demand for CytoSorb
The growing demand for CytoSorb is a key driver of CytoSorbents’ success. As the company continues to execute on its strategy, it is likely to benefit from the increasing adoption of its flagship product.
Stay Ahead of the Curve with Expert Insights
Get the latest stock recommendations from top Wall Street analysts, all in one place. Stay informed with weekly expert stock picks from the Smart Investor Newsletter.
Leave a Reply